top of page
cropped-EJP-RD-txt-horizontal.png
Logo principale.webp

EJP RD launched its second Joint Transnational Call (JTC2020) co-funded with the European Commission to fund multilateral “Pre-Clinical Research to Develop Effective Therapies for Rare Diseases”. The Project - TREATKCNQ : Targeted treatment for KCNQ related encephalopathies: retigabine analogues, repurposed drugs and allele specific knock down  received the approval and founded.

 

CENTRI KCNQ_.jpg

EJP RD launched its second Joint Transnational Call (JTC2020) co-funded with the European Commission to fund multilateral “Pre-Clinical Research to Develop Effective Therapies for Rare Diseases”. The Project -SCN1A-up! : Therapeutic strategies for Dravet syndrome: upregulation of endogenous SCN1A and modulation of remodeling received the approval and founded.

CENTRI SCN1A.jpg
logo-dravet_edited.png

Recognized as legal personality with provision of the Regional Council of Veneto dated 09.12.2015 n ° 815.

Agreement with the AOUI of Verona Prot. 1306 of 12/01/2021. Approved with Resolution no. 1392 of 12/30/2020

Quick Links

Contact us

📨 : info@dravetitalia.org

📞       : +39 3453589662

Senza nome.jpg
  • Instagram Icona sociale
  • Facebook
  • YouTube
  • Twitter

© 2021 Dravet Italia Onlus All Rights Reserved. CF 90018630237 -  Privacy Policy  -  Cookie Policy

bottom of page